CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the popular penny stocks on Robinhood to buy. On March 23, Piper Sandler analyst Joseph Catanzaro raised his price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $12 from $10, while maintaining an Overweight rating. This move followed encouraging Phase 1 clinical data from CytomX’s lead drug candidate, varsetatug maseatecan, or varseta-M.

CytomX Therapeutics (CTXM) Gains Analyst Confidence on Trial Progress

Pixabay/Public domain

Catanzaro noted that the data from CytomX’s lead drug candidate test showed dose-dependent efficacy. In particular, the 10mg/kg dose delivered a 32% objective response rate and an 84% disease control rate.​

Building on those results, CytomX has launched a Phase Ib study combining varseta-M with Avastin, or bevacizumab, the analyst noted. The company is planning to start a separate Phase Ib/II trial combining Avastin with chemotherapy in earlier-line colorectal cancer patients. Catanzaro noted that this is a sign the company is moving the drug up the treatment ladder rather than keeping it confined to late-stage patients.​

The analyst also noted that CytomX is preparing to present Phase 1 data on CX-801 combined with Merck’s KEYTRUDA in advanced melanoma patients by the end of 2026. This, said Catanzaro, adds a second clinical catalyst to the pipeline calendar.​

Separately, on the balance sheet, CytomX ended 2025 with $137 million in cash. The company then raised an additional $250 million through a stock offering where it priced 47.2 million shares and pre-funded warrants at $5.30 per share. This brought pro forma cash to approximately $372 million and gave the company ample runway to fund its ongoing and planned trials.

CytomX Therapeutics Inc. (NASDAQ:CTMX) is a clinical-stage biopharmaceutical company that develops antibody-based therapies for cancer treatment. Its proprietary Probody technology is designed to localize therapeutic activity to tumor tissue while minimizing effects on healthy cells.

While we acknowledge the risk and potential of CTMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CTMX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Robinhood Stocks with High Potential and 15 Best Forever Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.